Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

DCOYBearishCorporate Developmentsnews

High materiality7/10

Decoy Therapeutics secures up-to-$21M PIPE to push lead asset into trials

Jun 26, 2026, 8:20 PM EDT2 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The PIPE increases share count via upfront and milestone warrants, creating dilution risk; near-term trading could be pressured until closing details and milestone outcomes are clarified.

AI summary

What happened, with direct paths to the underlying reporting

Decoy Therapeutics announced a private placement financing (PIPE) with a single healthcare investor, expected to raise about $3.5 million upfront and up to $21 million total through milestone-based warrants. Proceeds are destined to advance Decoy's lead asset into clinical trials, leveraging its D-MAVs platform. The deal features milestone-triggered warrants that could dilute existing shareholders if exercised.

Decoy launches PIPE financing totaling up to $21M, with upfront $3.5M at $5.91/ share.
Warrant structure adds Series A/B/C milestones for additional ~ $17M potential.
Closing expected around June 29, 2026; Curvature Securities as sole placement agent.
Proceeds to advance lead asset into clinical trials; milestones hinge on regulatory approvals.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.